Related references
Note: Only part of the references are listed.Phase 1 study of CART-ddBCMA for the treatment of subjects with relapsed and refractory multiple myeloma
Matthew J. Frigault et al.
BLOOD ADVANCES (2023)
Anti-BCMA/CD19 CAR T Cells with Early Immunomodulatory Maintenance for Multiple Myeloma Responding to Initial or Later-Line Therapy
Alfred L. Garfall et al.
BLOOD CANCER DISCOVERY (2023)
Neoantigens: promising targets for cancer therapy
Na Xie et al.
SIGNAL TRANSDUCTION AND TARGETED THERAPY (2023)
Chimeric antigen receptor T-cells, bispecific antibodies, and antibody-drug conjugates for multiple myeloma: An update
Arjun Lakshman et al.
AMERICAN JOURNAL OF HEMATOLOGY (2022)
High efficacy and safety of CD38 and BCMA bispecific CAR-T in relapsed or refractory multiple myeloma
Yuanyan Tang et al.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2022)
A combination of humanized anti-BCMA and murine anti-CD38 CAR-T cell therapy in patients with relapsed or refractory multiple myeloma
Huan Zhang et al.
LEUKEMIA & LYMPHOMA (2022)
CAR-T cell therapy targeting B cell maturation antigen is effective for relapsed/refractory multiple myeloma, including cases with poor performance status
Juan Du et al.
AMERICAN JOURNAL OF HEMATOLOGY (2022)
Correlation of Cytokine Release Syndrome With Prognosis After Chimeric Antigen Receptor T Cell Therapy: Analysis of 54 Patients With Relapsed or Refractory Multiple Myeloma
Xue Wang et al.
FRONTIERS IN IMMUNOLOGY (2022)
Talquetamab, a T-Cell-Redirecting GPRC5D Bispecific Antibody
Ajai Chari et al.
NEW ENGLAND JOURNAL OF MEDICINE (2022)
Antibodies and bispecifics for multiple myeloma: effective effector therapy
Christopher Cipkar et al.
HEMATOLOGY-AMERICAN SOCIETY OF HEMATOLOGY EDUCATION PROGRAM (2022)
Manipulating T-cell metabolism to enhance immunotherapy in solid tumor
Chen Chen et al.
FRONTIERS IN IMMUNOLOGY (2022)
Teclistamab in Relapsed or Refractory Multiple Myeloma
Philippe Moreau et al.
NEW ENGLAND JOURNAL OF MEDICINE (2022)
γ-secretase inhibitors augment efficacy of BCMA-targeting bispecific antibodies against multiple myeloma cells without impairing T-cell activation and differentiation
Hailin Chen et al.
BLOOD CANCER JOURNAL (2022)
NAIRscore as a biomarker for the quality of immune response to neoantigens is related with an increased overall survival in multiple myeloma
Xingxing Jian et al.
MOLECULAR THERAPY-NUCLEIC ACIDS (2022)
Prolonged hematological toxicity in patients receiving BCMA/CD19 CAR-T-cell therapy for relapsed or refractory multiple myeloma
Hujun Li et al.
FRONTIERS IN IMMUNOLOGY (2022)
CAR T-Cell Therapy for Patients with Multiple Myeloma: Current Evidence and Challenges
Matthew J. Rendo et al.
BLOOD AND LYMPHATIC CANCER-TARGETS AND THERAPY (2022)
Cancer Statistics, 2021
Rebecca L. Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2021)
Personal neoantigen vaccines induce persistent memory T cell responses and epitope spreading in patients with melanoma
Zhuting Hu et al.
NATURE MEDICINE (2021)
A bispecific CAR-T cell therapy targeting BCMA and CD38 in relapsed or refractory multiple myeloma
Heng Mei et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2021)
Neoantigen: A New Breakthrough in Tumor Immunotherapy
Zheying Zhang et al.
FRONTIERS IN IMMUNOLOGY (2021)
Preclinical activity and determinants of response of the GPRC5DxCD3 bispecific antibody talquetamab in multiple myeloma
Christie P. M. Verkleij et al.
BLOOD ADVANCES (2021)
Teclistamab, a B-cell maturation antigenxCD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma (MajesTEC-1): a multicentre, open-label, single-arm, phase 1 study
Saad Z. Usmani et al.
LANCET (2021)
Immune checkpoint inhibitors in melanoma
Matteo S Carlino et al.
LANCET (2021)
Intron retention-induced neoantigen load correlates with unfavorable prognosis in multiple myeloma
Chuanpeng Dong et al.
ONCOGENE (2021)
Indatuximab ravtansine plus dexamethasone with lenalidomide or pomalidomide in relapsed or refractory multiple myeloma: a multicentre, phase 1/2a study
Kevin R. Kelly et al.
LANCET HAEMATOLOGY (2021)
Targeting public neoantigens for cancer immunotherapy
Alexander H. Pearlman et al.
NATURE CANCER (2021)
Personalized neoantigen pulsed dendritic cell vaccine for advanced lung cancer
Zhenyu Ding et al.
SIGNAL TRANSDUCTION AND TARGETED THERAPY (2021)
Mutation-derived Neoantigen-specific T-cell Responses in Multiple Myeloma
Deepak Perumal et al.
CLINICAL CANCER RESEARCH (2020)
Anti-B-Cell Maturation Antigen BiTE Molecule AMG 420 Induces Responses in Multiple Myeloma
Max S. Topp et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
The critical role of CD4+ T cells in PD-1 blockade against MHC-II-expressing tumors such as classic Hodgkin lymphoma
Joji Nagasaki et al.
BLOOD ADVANCES (2020)
Bispecifics, trispecifics, and other novel immune treatments in myeloma
Guido Lancman et al.
HEMATOLOGY-AMERICAN SOCIETY OF HEMATOLOGY EDUCATION PROGRAM (2020)
Systematically Characterizing A-to-I RNA Editing Neoantigens in Cancer
Chi Zhou et al.
FRONTIERS IN ONCOLOGY (2020)
Frontline therapy for newly diagnosed patients with multiple myeloma
Sung-Hoon Jung et al.
BLOOD RESEARCH (2020)
Trispecific antibodies enhance the therapeutic efficacy of tumor-directed T cells through T cell receptor co-stimulation
Lan Wu et al.
NATURE CANCER (2020)
A Phase I Study to Assess the Safety and Pharmacokinetics of Single-agent Lorvotuzumab Mertansine (IMGN901) in Patients with Relapsed and/or Refractory CD-56-positive Multiple Myeloma
Sikander Ailawadhi et al.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2019)
Indatuximab Ravtansine (BT062) Monotherapy in Patients With Relapsed and/or Refractory Multiple Myeloma
Sundar Jagannath et al.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2019)
Antibody-drug conjugate, GSK2857916, in relapsed/refractory multiple myeloma: an update on safety and efficacy from dose expansion phase I study
Suzanne Trudel et al.
BLOOD CANCER JOURNAL (2019)
Monoclonal gammopathy of undetermined significance
Tarek H. Mouhieddine et al.
BLOOD (2019)
B cell maturation antigen-specific CAR T cells are clinically active in multiple myeloma
Adam D. Cohen et al.
JOURNAL OF CLINICAL INVESTIGATION (2019)
Pediatric patients with acute lymphoblastic leukemia generate abundant and functional neoantigen-specific CD8+ T cell responses
Anthony E. Zamora et al.
SCIENCE TRANSLATIONAL MEDICINE (2019)
Determinants for Neoantigen Identification
Andrea Garcia-Garijo et al.
FRONTIERS IN IMMUNOLOGY (2019)
A combination of humanised anti-CD19 and anti-BCMA CAR T cells in patients with relapsed or refractory multiple myeloma: a single-arm, phase 2 trial
Zhiling Yan et al.
LANCET HAEMATOLOGY (2019)
Bispecific T-cell engagers: Towards understanding variables influencing the in vitro potency and tumor selectivity and their modulation to enhance their efficacy and safety
Diego Ellerman
METHODS (2019)
Bortezomib retreatment for relapsed and refractory multiple myeloma in real-world clinical practice
Cyrille Hulin et al.
HEALTH SCIENCE REPORTS (2019)
The Role of B-Cell Maturation Antigen in the Biology and Management of, and as a Potential Therapeutic Target in, Multiple Myeloma
Eric Sanchez et al.
TARGETED ONCOLOGY (2018)
Identification of novel mutational drivers reveals oncogene dependencies in multiple myeloma
Brian A. Walker et al.
BLOOD (2018)
Improvement in Overall Survival With Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma
David S. Siegel et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Hitting the Target: How T Cells Detect and Eliminate Tumors
Anthony E. Zamora et al.
JOURNAL OF IMMUNOLOGY (2018)
Analysis of the genomic landscape of multiple myeloma highlights novel prognostic markers and disease subgroups
Niccolo Bolli et al.
LEUKEMIA (2018)
Targeting B-cell maturation antigen with GSK2857916 antibody-drug conjugate in relapsed or refractory multiple myeloma (BMA117159): a dose escalation and expansion phase 1 trial
Suzanne Trudel et al.
LANCET ONCOLOGY (2018)
Complex structural variants in Mendelian disorders: identification and breakpoint resolution using short- and long-read genome sequencing
Alba Sanchis-Juan et al.
GENOME MEDICINE (2018)
Tumor Mutational Burden as an Independent Predictor of Response to Immunotherapy in Diverse Cancers
Aaron M. Goodman et al.
MOLECULAR CANCER THERAPEUTICS (2017)
Neoantigen prediction and the need for validation
Antonella Vitiello et al.
NATURE BIOTECHNOLOGY (2017)
High somatic mutation and neoantigen burden are correlated with decreased progression-free survival in multiple myeloma
A. Miller et al.
BLOOD CANCER JOURNAL (2017)
Multiple myeloma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
P. Moreau et al.
ANNALS OF ONCOLOGY (2017)
Targeting neoantigens to augment antitumour immunity
Mark Yarchoan et al.
NATURE REVIEWS CANCER (2017)
CD28 Costimulation: From Mechanism to Therapy
Jonathan H. Esensten et al.
IMMUNITY (2016)
Multiple myeloma epidemiology and survival: A unique malignancy
Dickran Kazandjian
SEMINARS IN ONCOLOGY (2016)
Advances in Therapeutic Fc engineering - Modulation of igG-Associated effector Functions and Serum Half-life
Abhishek Saxena et al.
FRONTIERS IN IMMUNOLOGY (2016)
Toxicity and management in CAR T-cell therapy
Challice L. Bonifant et al.
MOLECULAR THERAPY-ONCOLYTICS (2016)
Bispecific antibodies
Roland E. Kontermann et al.
DRUG DISCOVERY TODAY (2015)
Neoantigens in cancer immunotherapy
Ton N. Schumacher et al.
SCIENCE (2015)
OptiType: precision HLA typing from next-generation sequencing data
Andras Szolek et al.
BIOINFORMATICS (2014)
Cancer Statistics, 2014
Rebecca Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2014)
Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients
S. K. Kumar et al.
LEUKEMIA (2014)
The Basic Principles of Chimeric Antigen Receptor Design
Michel Sadelain et al.
CANCER DISCOVERY (2013)
HLA typing from RNA-Seq sequence reads
Sebastian Boegel et al.
GENOME MEDICINE (2012)
Derivation of HLA types from shotgun sequence datasets
Rene L. Warren et al.
GENOME MEDICINE (2012)
Antibody-drug conjugates: targeted drug delivery for cancer
Stephen C. Alley et al.
CURRENT OPINION IN CHEMICAL BIOLOGY (2010)
Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma
R. A. Kyle et al.
LEUKEMIA (2009)
BCMA is essential for the survival of long-lived bone marrow plasma cells
BP O'Connor et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2004)
Targeting tumours with genetically enhanced T lymphocytes
M Sadelain et al.
NATURE REVIEWS CANCER (2003)
Human CD38 and CD16 are functionally dependent and physically associated in natural killer cells
S Deaglio et al.
BLOOD (2002)
Tumor-specific T cell activation by recombinant immunoreceptors:: CD3ζ signaling and CD28 costimulation are simultaneously required for efficient IL-2 secretion and can ge integrated into one combined CD28/CD3ζ signaling receptor molecule
A Hombach et al.
JOURNAL OF IMMUNOLOGY (2001)